ArtVentive Medical Group, Inc. (OTC Bulletin Board: AVTD) today announced the addition of Mr. John Rappe to the executive team as Senior Vice President of Global Marketing and North American Sales.

"The Company's momentum requires global industry expertise to support the tremendous demand and growth that we are projecting," said Jim Graham, Chief Executive Officer, ArtVentive Medical Group, Inc. "With twenty years of success in sales, marketing and branding within the medical industry, John Rappe is an important addition to the ArtVentive Medical team signifying another pivotal moment in our corporate history."

Mr. Rappe will lead global marketing and the North American launch of the Company's EOS TM Peripheral Vascular Occlusion system, a self-expandable catheter-based device that facilitates immediate, reliable and permanent occlusion of body lumens. The Company received the European CE Mark certification in 2013 and is commencing shipping to its expanding European distribution network as it prepares the foundation to launch into the United States and other international markets early in 2014 following regulatory approval.

"ArtVentive is poised to become an international leader in the embolization market," said John Rappe, SVP Global Marketing and North American Sales. "The clinical benefits of the ArtVentive EOS TM device offer patients an alternative to major surgery. This is an exciting time to be joining such an innovative Company."

With a strong track record of success, Mr. Rappe was most recently with the Boston Scientific Corporation where he provided leadership and superior sales results over an eight-year period. Prior, Mr. Rappe served as Vice President of Sales and Marketing for Young Innovations, Inc., a leading global manufacturer and provider of preventative dental consumables and diagnostic imaging equipment.

"It is essential that we continue to expand our international management team with experienced professionals such as John in achieving our global corporate goals," continued Jim Graham, CEO, ArtVentive Medical Group, Inc.

About ArtVentive Medical Group, Inc.

ArtVentive Medical Group, Inc., with corporate headquarters in Carlsbad, California, is an innovative, multi-faceted medical device company committed to developing, manufacturing and marketing a family of devices globally, featuring the Endoluminal Occlusion Systems (EOS TM).

The EOS TM system is catheter-based and self-expandable and facilitates permanent or temporary occlusion of body lumens, a cavity found within the vascular system and organ network within the body. The ArtVentive EOS TM device will serve in many cases as a safe and reliable alternative to major surgery. This technological innovation is bringing the current interventional, image-guided techniques to a new level of sophistication, resolving significant, unaddressed health issues.

The ArtVentive EOS device targets the global market in several major clinical areas, including peripheral,neurological vascular, women's health (minimally invasive contraceptive and birth control), interventional cardiology, pulmonary and oncology.

More information about the Company can be found at www.artventivemedical.com.

Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements relate to the Company's current expectations, beliefs, projections and similar expressions concerning matters that are not historical facts and are not guarantees of future performance. Forward-looking statements involve uncertainties, risks, assumptions and contingencies, many of which are outside the Company's control and which cause actual results to differ materially from those described in or implied by any forward-looking statement. All forward-looking statements are based on currently available information and speak only as of the date on which they are made. The Company assumes no obligation to update any forward-looking statement made in this news release that becomes untrue because of subsequent events, new information or otherwise, except to the extent it is required to do so in connection with its ongoing requirements under federal securities laws. For a further discussion of these and other factors that could cause the Company's future results to differ materially from any forward-looking statements, see the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission.

ArtVentive Medical Group, Inc.
H.J. (Jim) Graham, CEO
760-471-7700
hjgraham@artventivemedical.com